Show simple item record

dc.contributor.authorRescigno, P
dc.contributor.authorde Bono, JS
dc.date.accessioned2019-05-01T13:50:46Z
dc.date.issued2019-02
dc.identifier.citationNature reviews. Urology, 2019, 16 (2), pp. 69 - 70
dc.identifier.issn1759-4812
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3214
dc.identifier.eissn1759-4820
dc.identifier.doi10.1038/s41585-018-0121-y
dc.formatPrint
dc.format.extent69 - 70
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
dc.subjectHumans
dc.subjectProstatic Neoplasms
dc.subjectImmunotherapy
dc.subjectMale
dc.titleImmunotherapy for lethal prostate cancer.
dc.typeJournal Article
rioxxterms.versionofrecord10.1038/s41585-018-0121-y
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
rioxxterms.licenseref.startdate2019-02
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfNature reviews. Urology
pubs.issue2
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.publication-statusPublished
pubs.volume16
pubs.embargo.termsNot known
icr.researchteamProstate Cancer Targeted Therapy Groupen_US
dc.contributor.icrauthorRescigno, Pasquale
dc.contributor.icrauthorDe Bono, Johann


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record